You have 9 free searches left this month | for more free features.

NK

Showing 1 - 25 of 3,975

STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS

Extranodal NK T Cell Lymphoma, NK-Cell Leukemia Trial in Xuzhou (Anti-CD56 CAR T)

Recruiting
  • Extranodal NK T Cell Lymphoma
  • NK-Cell Leukemia
  • Anti-CD56 CAR T
  • Xuzhou, Jiangsu, China
    The Affiliated Hospital of Xuzhou Medical University
Jul 10, 2023

AML, Adult, Minimal Residual Disease Trial in Tianjin (CD33/CLL1 dual CAR-NK cell, Cyclophosphamid, Fludarabine)

Not yet recruiting
  • AML, Adult
  • Minimal Residual Disease
  • CD33/CLL1 dual CAR-NK cell
  • +5 more
  • Tianjin, China
    Institute of Hematology & Blood Diseases Hospital
Aug 4, 2023

Synovial Sarcoma Trial in Houston (Fludarabine phosphate, NY-ESO-1 TCR/IL-15 NK, Cyclophosphamide)

Not yet recruiting
  • Synovial Sarcoma
  • Fludarabine phosphate
  • +2 more
  • Houston, Texas
    MD Anderson Cancer Center
Oct 9, 2023

Immunotherapy, Multiple Myeloma Trial in Zhengzhou (Chimeric Antigen Receptor NK Cell Injection Targeting BCMA (BCMA CAR-NK))

Recruiting
  • Immunotherapy
  • Multiple Myeloma
  • Chimeric Antigen Receptor NK Cell Injection Targeting BCMA (BCMA CAR-NK)
  • Zhengzhou, Henan, China
    Henan Cancer Hospital
Dec 14, 2022

Multiple Myeloma, Plasma Cell Leukemia Trial in Shanghai (Human BCMA targeted CAR-NK cells injection)

Recruiting
  • Multiple Myeloma
  • Plasma Cell Leukemia
  • Human BCMA targeted CAR-NK cells injection
  • Shanghai, Shanghai, China
    Shanghai Changzheng Hospital
Sep 13, 2023

Leukemia Trial (Donor Enriched Activated Natural Killer Cell Infusion)

Withdrawn
  • Leukemia
  • Donor Enriched Activated Natural Killer Cell Infusion
  • (no location specified)
Dec 20, 2022

Ovarian Cancer Trial in Hangzhou (NKG2D CAR-NK)

Recruiting
  • Ovarian Cancer
  • NKG2D CAR-NK
  • Hangzhou, Zhejiang, China
    Zhejiang Cancer Hospital
Mar 26, 2023

AML, Adult Trial in Hangzhou (CLL1 CAR-NK cell injection)

Recruiting
  • AML, Adult
  • CLL1 CAR-NK cell injection
  • Hangzhou, Zhejiang, China
    Clinical research ethics committee of the first affiliated hospi
Aug 30, 2023

NK Cell, B-cell Lymphoma Recurrent, B-cell Lymphoma Refractory Trial in Hubei (autologous NK cell)

Not yet recruiting
  • NK Cell
  • +2 more
  • autologous NK cell
  • Hubei, Xiangyang, China
    EC of Xiangyang No.1 People's Hospital Hubei University of Medic
Jun 19, 2023

NK-T-Cell Lymphoma, Extranodal Trial in Shanghai (4 cycles of ESA regimen with sandwiched radiotherapy, 2 cycles of ESA regimen

Not yet recruiting
  • NK-T-Cell Lymphoma, Extranodal
  • 4 cycles of ESA regimen with sandwiched radiotherapy
  • +2 more
  • Shanghai, Shanghai, China
    Ruijin Hospital
Sep 29, 2023

Malignant Sarcoma Trial in Madrid (Natural Killer (NK) cells (a new immunotherapy))

Recruiting
  • Malignant Sarcoma
  • Natural Killer (NK) cells (a new immunotherapy)
  • Madrid, Spain
    Hospital Universitario La Paz
Jul 19, 2023

Myeloma Trial in Houston (Fludarabine phosphate, Cyclophosphamide, NY-ESO-1 TCR/IL-15 NK)

Not yet recruiting
  • Myeloma
  • Fludarabine phosphate
  • +2 more
  • Houston, Texas
    M D Anderson Cancer Center
Sep 27, 2023

Aggressive NK Cell Leukemia Trial in Hiroshima (PPMX-T003)

Recruiting
  • Aggressive NK Cell Leukemia
  • Hiroshima, Japan
    Hiroshima University Hospital
May 9, 2023

Osteosarcoma, Soft Tissue Sarcoma Trial in Shanghai (NK510)

Recruiting
  • Osteosarcoma
  • Soft Tissue Sarcoma
  • Shanghai, China
    Shanghai General Hospital
Oct 31, 2023

Solid Tumors Trial in Houston (Rimiducid, TROP2-CAR-NK Cells, Fludarabine phosphate)

Not yet recruiting
  • Solid Tumors
  • Houston, Texas
    M D Anderson Cancer Center
Sep 27, 2023

Acute Myeloid Leukemia, Blastic Plasmacytoid Dendritic Cell Tumor (BPDCN), Relapse Leukemia Trial in Taiyuan (CD123 targeted

Recruiting
  • Acute Myeloid Leukemia
  • +3 more
  • CD123 targeted CAR-NK cells
  • Taiyuan, Shanxi, China
    Shanxi Bethune Hospital
Aug 28, 2023

nk/T-cell Lymphoma, Newly Diagnosed, Advanced Lymphoma Trial in Beijing (XPO1 inhibitor)

Recruiting
  • nk/T-cell Lymphoma
  • +2 more
  • XPO1 inhibitor
  • Beijing, Haidian, China
    ChinaPLAGH
Apr 18, 2023

Colorectal Cancer Trial (anesthetic method)

Withdrawn
  • Colorectal Cancer
  • anesthetic method
  • (no location specified)
Jul 11, 2023

Acute Myeloid Leukemia Trial in Houston (Azacitidine, Venetoclax, NK Cells)

Not yet recruiting
  • Acute Myeloid Leukemia
  • Houston, Texas
    M.D. Anderson Cancer Center
Apr 17, 2023

Refractory or Relapsed B-cell Non-Hodgkin Lymphoma Trial in Shanghai (dualCAR-NK19/70 cell)

Recruiting
  • Refractory or Relapsed B-cell Non-Hodgkin Lymphoma
  • dualCAR-NK19/70 cell
  • Shanghai, Shanghai, China
    Shanghai Tongji Hospital, Tongji University School of Medicine
Apr 24, 2023

Anatomic Stage IV Breast Cancer AJCC v8, HER2-Negative Breast Carcinoma Trial in Columbus (procedure, drug, biological)

Not yet recruiting
  • Anatomic Stage IV Breast Cancer AJCC v8
  • HER2-Negative Breast Carcinoma
  • Biospecimen Collection
  • +5 more
  • Columbus, Ohio
    Ohio State University Comprehensive Cancer Center
Aug 30, 2023

Extranodal NK/T-cell Lymphoma Trial (Sugemalimab, Placebo, Pegaspargase)

Not yet recruiting
  • Extranodal NK/T-cell Lymphoma
  • Sugemalimab
  • +4 more
  • (no location specified)
Jan 17, 2023

T-Cell and NK-Cell Tumor Trial

Not yet recruiting
  • T-Cell and NK-Cell Neoplasm
    • (no location specified)
    Sep 28, 2023

    NK-T-Cell Lymphoma, Extranodal Trial (Pegaspargase Combined With Gemcitabine, Etoposide, Liposomal Mitoxantrone Hydrochloride

    Not yet recruiting
    • NK-T-Cell Lymphoma, Extranodal
    • Pegaspargase Combined With Gemcitabine, Etoposide, Liposomal Mitoxantrone Hydrochloride and Dexamethasone (P-GEMD) regimen
    • (no location specified)
    Mar 7, 2023

    B-Cell Lymphoblastic Leukemia/Lymphoma Trial in Kunming (Anti-CD19 UCAR-NK cells)

    Recruiting
    • B-Cell Lymphoblastic Leukemia/Lymphoma
    • Anti-CD19 UCAR-NK cells
    • Kunming, Yunnan, China
      920th Hospital of Joint Logistics Support Force of People's Libe
    Dec 19, 2022